Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01708590 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 661
- Enrollment target
NCT01708590 is a Phase 3 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 661 participants.
The verdict
NCT01708590, a Phase 3 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 661 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
Interventions
- DRUG placebo
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01708590
The ClinicalTrials.gov registry entry for NCT01708590 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01708590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01708590 about?
NCT01708590 is a clinical study titled "Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects". The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.
What is the current status of trial NCT01708590?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2012-08. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01708590?
The interventions under investigation include: placebo (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT01708590?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.